var data={"title":"Fluoxymesterone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluoxymesterone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6217?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluoxymesterone-drug-information\" class=\"drug drug_general\">see &quot;Fluoxymesterone: Drug information&quot;</a> and <a href=\"topic.htm?path=fluoxymesterone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluoxymesterone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172812\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Androxy [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058754\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Androgen</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058749\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluoxymesterone-drug-information\" class=\"drug drug_general\">see &quot;Fluoxymesterone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosage and duration of therapy depend upon age, sex, diagnosis, patient&rsquo;s response to therapy, and appearance of adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Delayed puberty: </b>Adolescent Males: Typically not recommended for use before 14 years of age (Palmert 2012): Oral: Usual range: 2.5 mg to 10 mg daily, dose may be administered once daily or divided; reported range: 2.5 to 20 mg; most experts recommend a daily a dose of 2.5 mg for 6 to 60 months dependent upon clinical response (Melmed 2011; Strickland 1993); with testosterone therapy, response may be evaluated every 3 to 6 months and dose titrated as appropriate (Palmert 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Male hypogonadism:</b> Children &ge;12 years and Adolescents (Han 2010; Young 2012): Oral: 2.5 to 20 mg daily; dose may be administered once daily or in divided doses for 4 to 6 months; some experts suggest beginning testosterone therapy with low doses and titrating gradually to prevent rapid over-virilization (Young 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Breast cancer, metastatic (females</b>): Oral: Manufacturer labeling: 10 to 40 mg daily in divided doses for &ge;3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Delayed puberty (males): </b>Oral: 2.5 to 20 mg daily for 4 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypogonadism, primary or hypogonadotropic (males): </b>Oral: 5 to 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edema: All patients: If therapy is discontinued due to edema, may reinitiate (if indicated) at a reduced dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypogonadism: In adult males, the following have been suggested: Hematocrit (HCT) &gt;50%: Use is not recommended; if HCT &gt;54% during therapy, discontinue until HCT falls to a safe level, assess for hypoxia and sleep apnea; if reinitiating therapy, reduce the dose (Bhasin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Children &ge;12 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment prior to therapy: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment during therapy: Discontinue use if abnormal liver function tests or cholestatic hepatitis with jaundice occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172797\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Androxy: 10 mg [DSC] [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172780\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172840\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684550\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May take without regard to food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104522\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172808\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058757\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Testosterone hormone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) (FDA approved in male pediatric patients [age not specified] and adults); treatment of delayed puberty (FDA approved in male pediatric patients [age not specified]); and palliative treatment of inoperable metastatic female breast cancer (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172847\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Halotestin [Great Britain] may be confused with Haldol brand name for haloperidol [U.S. and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172844\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, headache, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, androgenetic alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido (decreased libido or increased libido), electrolyte disturbance (calcium, chloride, inorganic phosphate, potassium, and sodium retention), fluid retention, gynecomastia (males), hirsutism, hypercholesterolemia, menstrual disease (females; including amenorrhea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastrointestinal irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Benign prostatic hypertrophy (males), oligospermia (males; at higher doses), priapism (males), testicular atrophy (males), virilization (females; including clitoromegaly, deepening of the voice in females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Clotting factors suppression, polycythemia, prostate carcinoma (males)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, hepatic insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction (non-immunologic anaphylaxis), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatic coma, hepatocellular neoplasm, hepatotoxicity (idiosyncratic; Chalasani 2014), peliosis hepatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172801\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Males with carcinoma of the breast or the prostate (known or suspected); women who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172784\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Anabolic steroids may alter serum lipid profile; use caution in patients with history of myocardial infarction or coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gynecomastia: May cause gynecomastia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Prolonged use of high doses of oral androgens has been associated with serious hepatic effects (eg, peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Discontinue use in patients with cholestatic hepatitis with jaundice or abnormal liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in patients with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Not recommended for androgen replacement in hypogonadal males with uncontrolled or poorly controlled heart failure (Bhasin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Use with caution in patients with breast cancer or immobilization; may cause hypercalcemia by stimulating osteolysis. Discontinue use if hypercalcemia occurs; may indicate bony metastasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in renal impairment; not recommended for androgen replacement in hypogonadal males with severe lower urinary tract symptoms (eg, International Prostate Symptom Score [IPSS] &gt;19) (Bhasin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep apnea: Not recommended for androgen replacement in hypogonadal males with untreated severe obstructive sleep apnea (Bhasin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly males may be at greater risk for prostatic hyperplasia and prostate cancer; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children. In prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women: During treatment for metastatic breast cancer, women should be monitored for signs of virilization (eg, deepening of voice, hirsutism, acne, clitoromegaly, menstrual irregularities); discontinue use with evidence of mild virilization to prevent irreversible symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility: Large doses of exogenous androgens may suppress spermatogenesis; not recommended for androgen replacement in hypogonadal males desiring fertility (Bhasin 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299354\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172789\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13316&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172792\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13386438\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are or may become pregnant. May cause androgenic effects to the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058753\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, cholesterol, hemoglobin, and hematocrit (prior to therapy, at 3 to 6 months, then annually); radiologic examination of wrist and hand every 6 months (when using in pediatric patients). Withhold initial treatment with hematocrit &gt;50%, hyperviscosity, untreated obstructive sleep apnea, or uncontrolled severe heart failure. Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3 to 6 months after initiation and then annually.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Bone mineral density: Monitor after 1 to 2 years of therapy in hypogonadal men with osteoporosis or low trauma fracture (Bhasin 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684551\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total testosterone, males:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">12 to 13 years: &lt;800 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">14 years: &lt;1,200 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to 16 years: 100 to 1,200 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">17 to 18 years: 300 to 1,200 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 40 years: 300 to 950 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;40 years: 240 to 950 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Free testosterone, males: 9 to 30 ng/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172783\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic derivative of testosterone; responsible for the normal growth and development of male sex hormones, male sex organs, and maintenance of secondary sex characteristics; large doses suppress endogenous testosterone release </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172800\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; enterohepatic recirculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 10 hours (range: 10-100 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90%); feces (6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5686408\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Androxy Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $577.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539862\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afluteston (AT);</li>\n      <li>Baojen (TW);</li>\n      <li>Fuloan (TW);</li>\n      <li>Halotestin (AU, BH, CI, CY, ET, FR, GH, GM, GN, GR, HU, IT, KE, LR, LY, ML, MR, MU, MW, NE, NG, NL, NO, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Oralsterone (TW);</li>\n      <li>Sidomon (TW);</li>\n      <li>Vewon (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Androxy tablets (fluoxymesterone) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, Inc.; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhasin S, Cunningham GR, Hayes FJ, et al, &quot;Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,&quot; <i>J Clin Endocrinol Metab</i>, 2010, 95(6):2536-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/20525905/pubmed\" target=\"_blank\" id=\"20525905\">20525905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? <i>Clin Endocrinol (Oxf)</i>. 2010;72(6):731-737.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/19912242/pubmed\" target=\"_blank\" id=\"19912242\">19912242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melmed S, Pololnsky KS, Larsen PR, Kronenberg HM, eds. &quot;Treatment of Delayed Puberty and Sexual Infantilism&quot; in <i>Williams Textbook of NEdocrinology</i>. 12th edition. Elsevier; 2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/8464656/pubmed\" target=\"_blank\" id=\"8464656\">8464656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/22296078/pubmed\" target=\"_blank\" id=\"22296078\">22296078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strickland AL, &quot;Long-Term Results of Treatment With Low-Dose Fluoxymesterone in Constitutional Delay of Growth and Puberty and in Genetic Short Stature,&quot; <i>Pediatrics</i>, 1993, 91(4):716-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/8464656/pubmed\" target=\"_blank\" id=\"8464656\">8464656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. <i>J Clin Endocrinol Metab</i>. 2012;97(3):707-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxymesterone-pediatric-drug-information/abstract-text/22392951/pubmed\" target=\"_blank\" id=\"22392951\">22392951</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13316 Version 85.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172812\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058754\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058749\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172797\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F172780\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F172840\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50684550\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104522\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F172808\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058757\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F172847\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172844\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172801\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172784\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299354\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172789\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172792\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13386438\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058753\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50684551\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172783\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F172800\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5686408\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539862\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13316|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluoxymesterone-drug-information\" class=\"drug drug_general\">Fluoxymesterone: Drug information</a></li><li><a href=\"topic.htm?path=fluoxymesterone-patient-drug-information\" class=\"drug drug_patient\">Fluoxymesterone: Patient drug information</a></li></ul></div></div>","javascript":null}